CD4 and cancer: Thus, the latest studies have challenged the accepted paradigms of T helper cell differentiation and as such, assessing CD4+ TIL in cancer tissue will necessitate the evaluation of a number of specific phenotypic markers in addition to CD4+ to study the biological and prognostic relevance of each subset.